Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 12,241 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2, Cohort 3b: Carfilzomib 27 mg/m2
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
Interventions
Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Other
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
2,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Conditions
Osteogenesis Imperfecta (OI)
Interventions
AGA2115, Placebo
Drug · Other
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more
Conditions
Obesity, Overweight
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
MET233 and MET097, Placebo, MET097
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
Conditions
Carcinoma, Midline
Interventions
GSK525762
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases
Interventions
AGS-16M18
Biological
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Non-small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Biological · Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Boca Raton, Florida + 13 more
Conditions
Smoldering Multiple Myeloma
Interventions
Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Renal Cell Carcinoma
Interventions
Opdivo, Yervoy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Jacksonville, Florida • Iowa City, Iowa • Charlotte, North Carolina + 1 more
Conditions
Multiple Myeloma
Interventions
Ibrutinib, Pomalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 2 more
Conditions
Cholangiocarcinoma
Interventions
Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
Drug
Lead sponsor
PCI Biotech AS
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Conditions
Multiple Myeloma
Interventions
TTI-622, Daratumumab Hyaluronidase-fihj
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions
ABT-335, Rosuvastatin Calcium, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Observation of Ocrelizumab as Treatment in RRMS Patients
Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Renal Cell Carcinoma
Interventions
ASONEP
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Duarte, California • Fort Myers, Florida • Inverness, Florida + 2 more
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Conditions
Arrhythmias
Interventions
azimilide dihydrochloride
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
50
States / cities
Mobile, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
Conditions
Multiple Myeloma
Interventions
Non-Interventional Study
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
11
States / cities
Goodyear, Arizona • Duarte, California • Huntington Beach, California + 8 more
Conditions
Multiple Sclerosis
Interventions
Cognitive behavioral therapy for insomnia, Cognitive behavioral therapy for insomnia + biweekly support
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado